Biotech Archives - Page 9 of 733

2 minute read

Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations

June 6, 1:19 PM

Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.

NVS

1 minute read

AbbVie’s Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients

By Vandana Singh

June 6, 1:02 PM

AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.

ABBV

2 minute read

Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released

By Vandana Singh

June 6, 12:43 PM

4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.

FDMT

2 minute read

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?

By Vandana Singh

June 6, 12:16 PM

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was well-tolerated.

BMY

1 minute read

Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal

By Vandana Singh

June 6, 12:13 PM

Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions.

VNDA

2 minute read

Eli Lilly’s Alzheimer’s Drug, Donanemab Faces FDA’s Adcomm Vote Next Week On Data, Risk Profile

By Vandana Singh

June 6, 12:07 PM

The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10. This review assesses the drug's benefit-risk profile based on significant efficacy results in cognition and daily function.

LLY

2 minute read

Novavax Stock Soars On FDA COVID-19 Update: Fundamental Rally Or Potential Short Squeeze?

By Surbhi Jain

June 6, 11:26 AM

Novavax (NASDAQ: NVAX) stock surges on positive COVID-19 vaccine news, with FDA setting a PDUFA review date for April 2025. High trading volume and strong technical indicators make it a compelling investment opportunity.

NVAX

2 minute read

FDA Selects Moderna’s Rare Disease Candidate For Accelerated Development Program

By Vandana Singh

June 6, 9:59 AM

Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2024 pivotal study.

MRNA

2 minute read

What’s Going On With Sagimet Biosciences Stock On Thursday?

By Vandana Singh

June 6, 9:52 AM

Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress.

SGMT

1 minute read

AbbVie Announces Topline Results From Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine For High Folate Receptor-Alpha Expressing Platinum-Sensitive Ovarian Cancer; PICCOLO Met Its Primary Endpoint With An ORR Of 51.9%; The Median DOR, A Key S…

By Benzinga Newsdesk

June 6, 8:47 AM

PICCOLO trial met its primary endpoint of objective response rate (ORR)Data from the study will be presented at a future medical meetingNORTH CHICAGO, Ill., June 6, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced

ABBV